CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride clinical trials

A Double-blind, Placebo-Controlled, Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

This study is looking at two new medicines, SRP-4045 and SRP-4053, for Duchenne muscular dystrophy. It wants to see if they can help boys with certain types of Duchenne walk better and for longer. The study will compare these medicines to a dummy treatment.